Drug Profile


Alternative Names: Artrolasi; Copper zinc SOD; Cu/Zn-superoxide dismutase; Interceptor; Ontosein; Orgo-M; Ormetein; Peroxinorm; Serosod; Superoxide dismutase - GT Biopharma

Latest Information Update: 10 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OXIS International
  • Developer Tedec Meiji
  • Class Anti-inflammatories; Antirheumatics; Metalloproteins; Radioprotectives
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cystitis; Radiation injuries; Rheumatic disorders
  • Discontinued Reperfusion injury

Most Recent Events

  • 07 Aug 2017 Oxis International is now called GT Biopharma
  • 31 Mar 2011 Orgotein is available for licensing as of 31 Mar 2011.
  • 22 Mar 2004 OXIS International has been acquired by Axonyx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top